Modrasone (Alclometasone Dipropionate)

Alclometasone dipropionate penetrates the epidermis and binds to intracellular glucocorticoid receptors. The drug‑receptor complex alters gene transcription, suppressing pro‑inflammatory cytokines, reducing leukocyte migration, and inhibiting fibroblast proliferation, which together provide anti‑inflammatory and immunosuppressive effects.

The appropriate dose and frequency of Modrasone are determined by the prescribing healthcare professional based on the severity of the condition, the area of skin involved, and patient‑specific factors. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for alclometasone dipropionate in pregnancy and lactation are limited. Use only if the potential benefit justifies the potential risk to the fetus or infant, and always under the guidance of a qualified healthcare provider.

To order Modrasone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Alclometasone dipropionate is a mid‑potency corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents like hydrocortisone 1% while generally having a lower risk of skin atrophy than high‑potency steroids. Choice of therapy depends on disease severity, body area treated and physician assessment.

Store Modrasone below 25 °C in its original packaging, protecting it from moisture, heat and direct sunlight. Do not freeze. Keep the container tightly closed and keep out of reach of children.

Apply a thin layer of the cream or ointment to the affected skin area once or twice daily, as directed by the prescriber. Gently rub in until fully absorbed, and wash hands after application unless the hands are being treated.

Serious risks include skin atrophy, telangiectasia, secondary skin infections, systemic adrenal suppression with extensive use, and rare hypersensitivity reactions. Patients should report signs of thinning skin, unusual bruising, or systemic symptoms such as fatigue or weakness to their healthcare provider promptly.

Modrasone should be avoided in individuals with known hypersensitivity to alclometasone dipropionate or any formulation excipients, in untreated fungal, viral or bacterial skin infections, and in patients with severe skin atrophy or uncontrolled systemic infections unless directed by a physician.